Vaccination is a well-established means for prevention and spread of disease in people traveling abroad. Although vaccines to diseases such as cholera are recommended by world health agencies, they are seldom required even when traveling to endemic regions. Consequences of noncompliance can affect traveler's health and spread diseases to new regions, as occurred in Haiti in 2010 when United Nations peacekeepers from Nepal, where a cholera outbreak was underway, introduced the disease to the region. Steps to increase vaccine recommendation compliance should therefore be an integral part of vaccine development. PXVX0200 contains Center for Vaccine Development 103-HgR live, attenuated recombinant Vibrio cholerae vaccine strain, and is indicated for single-dose immunization against the bacteria that causes cholera. It is supplied as one buffer and one active component packet to be mixed into water and ingested. Administration instructions are designed to be "user friendly" with flexibility for self-administration, thus promoting compliance. Studies to support self-administration were conducted to cover stability of the vaccine outside of normal storage conditions, potency in case of misadministration, and disposal procedures to minimize environmental impact. The principal findings showed that the stability of vaccine was maintained under conditions allowing for transport times and temperature conditions as well as when misadministration errors were made. Finally, the vaccine was effectively neutralized with hot water and soap to prevent bacterial environmental contamination in the event of an accidental spill. The conclusion is that PXVX0200 oral vaccine is stable, easy to formulate and dispose of, and is amenable to self-administration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045606 | PMC |
http://dx.doi.org/10.4269/ajtmh.20-1223 | DOI Listing |
NPJ Prim Care Respir Med
January 2025
Université Paris Cité, Department of general practice, Paris, France, Paris, France.
Streptococcus pneumoniae (SP) remains an important cause of community acquired pneumonia (CAP). We aimed to describe the prevalence and characteristics of outpatients with radiologically confirmed pneumococcal CAP. Between November 2017 and December 2019, a French network of general practitioners enrolled CAP-suspected adults, with ≥1 clinical signs of infection and ≥1 signs of pulmonary localization in an observational study.
View Article and Find Full Text PDFBDJ Open
January 2025
Fukuoka Nursing College, Graduate School of Nursing, 2-15-1 Tamura, Sawara-ku, Fukuoka, 814-0193, Japan.
Background: Oral health professionals should have good COVID-19 vaccine literacy as should physicians and nurses. However, little is known about COVID-19 literacy and vaccine hesitancy among oral health professionals in Japan.
Aims: This study aimed to investigate the status of COVID-19 literacy and vaccine hesitancy among oral health professionals by comparing them with other healthcare workers (HCWs).
Vet Res
January 2025
College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, Iksan, 54596, Republic of Korea.
Fowl typhoid (FT) poses a significant threat to the poultry industry and can cause substantial economic losses, especially in developing regions. Caused by Salmonella Gallinarum (SG), vaccination can prevent FT. However, existing vaccines, like the SG9R strain, have limitations, including residual virulence and potential reversion of pathogenicity.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models.
View Article and Find Full Text PDFTransplant Proc
January 2025
Gastroenterolgy and Hepatology Department, Group of Clinical and Translational Research in Liver Diseases, Research Institution Valdecilla (IDIVAL), University Hospital Marqués de Valdecilla, Santander, Spain. Electronic address:
Background: The Omicron variant of SARS-CoV-2 emerged as a new variant of concern, characterized by high transmissibility and lower severity compared with previous variants, and became the majority variant in the sixth wave in Spain. This study aims to assess the impact of SARS-CoV-2 infection on liver transplant recipients (LTRs) during 2023 in the population of Cantabria.
Methods: The study included 295 LTRs undergoing follow-up at the Liver Transplant Unit of the Marqués de Valdecilla University Hospital.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!